FindTrial
Sign In

a mutation-annotated prognostic score (MAPS) for intrahepatic cholangiocarcinoma

Development and validation of a mutation-annotated prognostic score (MAPS) for intrahepatic cholangiocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070574
Enrollment
Unknown
Registered
2023-04-17
Start date
2023-04-28
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrahepatic cholangiocarcinoma

Interventions

Case series:None

Sponsors

Huashan Hospital Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: retrospectively include and analyze ICC patients undergoing curative resection betweeen 2014-2022 in our center. 1) 18-80 years old, male or female; 2) undergoing curative hepatectomy and pathologically diagnosed as ICC in our center; 3) no distant metastasis; 4) no history of other malignancies.

Exclusion criteria

Exclusion criteria: 1) no enough tumor sample can be used for further analysis; 2) patients who underwent palliative resection or biopsy only; 3) patients who underwent transplantation; 4) postoperative survival less than 1 month 5) other conditions that the investigators considered that were not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
TP53 mutation status;KRAS mutation status;overall survival;—

Secondary

MeasureTime frame
recurrence free survival;—

Countries

China

Contacts

Public ContactLunxiu Qin

Huashan Hospital Fudan University

qinlx@fudan.edu.cn+86 13761801800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026